search
Back to results

The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity

Primary Purpose

Dentine Hypersensitivity

Status
Completed
Phase
Phase 3
Locations
Ireland
Study Type
Interventional
Intervention
Stannous Fluoride
Sodium Monofluorophosphate
Sponsored by
GlaxoSmithKline
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dentine Hypersensitivity

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion

  • Demonstrates understanding of the study and willingness to participate
  • Aged at least 18 to 65 years
  • Understands and is willing, able and likely to comply with all study procedures and restrictions
  • Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral examination.
  • Self-reported history of dentinal hypersensitivity lasting more than 6 months but not more than 10 years
  • Minimum of 20 natural teeth at screening, a minimum of two accessible teeth (incisors, canines, pre-molars)
  • At baseline, participant has two non-adjacent sensitive teeth from those meeting the EAR, GI and mobility criteria at screening, with sensitivity measured by tactile stimulus (Yeaple ≤ 20g) and evaporative (air) assessment (Schiff Sensitivity Score ≥ 2) at baseline

Exclusion

  • Pregnant or breast-feeding women
  • Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit
  • Recent history (within the last year) of alcohol or other substance abuse
  • An employee of the sponsor or the study site or members of their immediate family
  • Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes.
  • Any condition which, in the opinion of the investigator, causes xerostomia
  • Dental prophylaxis within 4 weeks of screening
  • Tongue or lip piercing or presence of dental implants
  • Professional desensitising treatment within 12 weeks of screening
  • Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of screening, scaling or root planning within 3 months of screening.
  • Teeth bleaching within 12 weeks of screening
  • Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of screening
  • Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine
  • Sensitive tooth not expected to respond to treatment with an over-the counter dentifrice in the opinion of the investigator.
  • Use of a desensitising dentifrice within six weeks of screening (participant will be required to bring their current dentifrice to the site in order to verify the lack of known anti-sensitivity ingredients)
  • Daily doses of a medication which, in the opinion of the investigator, could interfere with the perception of pain
  • Currently taking antibiotics or have taken antibiotics within 2 weeks of baseline.
  • Daily doses of a medication which, in the opinion of the investigator, causes xerostomia
  • Individuals who require antibiotic prophylaxis for dental procedures
  • Any participant who, in the judgment of the investigator, should not participate in the study.

Sites / Locations

  • GSK Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Dentifrice containing stannous fluoride

Dentifrice containing Sodium Monofluorophosphate

Arm Description

Toothpaste

Toothpaste

Outcomes

Primary Outcome Measures

Change From Baseline in Schiff Sensitivity Score on Day 14
Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

Secondary Outcome Measures

Change From Baseline in Schiff Sensitivity Score on Post First Brushing (After 5 Minutes) and Day 3
Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicate improvement in sensitivity.
Change From Baseline in Tactile (Yeaple) Pain Threshold on Post First Brushing (After 5 Minutes), Day 3 and Day 14
Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.

Full Information

First Posted
March 2, 2017
Last Updated
February 5, 2018
Sponsor
GlaxoSmithKline
search

1. Study Identification

Unique Protocol Identification Number
NCT03072719
Brief Title
The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity
Official Title
A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Immediate and Short Term Relief From Dentinal Hypersensitivity
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
March 1, 2012 (Actual)
Primary Completion Date
June 1, 2012 (Actual)
Study Completion Date
June 12, 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GlaxoSmithKline

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A randomised, examiner blind, two treatment arm, stratified, parallel design, single-site study in subjects with at least two sensitive teeth to compare the efficacy of a test dentifrice against that of a control dentifrice in reducing dentinal hypersensitivity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dentine Hypersensitivity

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dentifrice containing stannous fluoride
Arm Type
Experimental
Arm Description
Toothpaste
Arm Title
Dentifrice containing Sodium Monofluorophosphate
Arm Type
Active Comparator
Arm Description
Toothpaste
Intervention Type
Drug
Intervention Name(s)
Stannous Fluoride
Intervention Description
Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
Intervention Type
Drug
Intervention Name(s)
Sodium Monofluorophosphate
Intervention Description
Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
Primary Outcome Measure Information:
Title
Change From Baseline in Schiff Sensitivity Score on Day 14
Description
Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.
Time Frame
Baseline, Day 14
Secondary Outcome Measure Information:
Title
Change From Baseline in Schiff Sensitivity Score on Post First Brushing (After 5 Minutes) and Day 3
Description
Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicate improvement in sensitivity.
Time Frame
Baseline, post first brushing (after 5 minutes) and Day 3
Title
Change From Baseline in Tactile (Yeaple) Pain Threshold on Post First Brushing (After 5 Minutes), Day 3 and Day 14
Description
Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.
Time Frame
Baseline, post first brushing (after 5 minutes), Day 3 and Day 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Demonstrates understanding of the study and willingness to participate Aged at least 18 to 65 years Understands and is willing, able and likely to comply with all study procedures and restrictions Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral examination. Self-reported history of dentinal hypersensitivity lasting more than 6 months but not more than 10 years Minimum of 20 natural teeth at screening, a minimum of two accessible teeth (incisors, canines, pre-molars) At baseline, participant has two non-adjacent sensitive teeth from those meeting the EAR, GI and mobility criteria at screening, with sensitivity measured by tactile stimulus (Yeaple ≤ 20g) and evaporative (air) assessment (Schiff Sensitivity Score ≥ 2) at baseline Exclusion Pregnant or breast-feeding women Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit Recent history (within the last year) of alcohol or other substance abuse An employee of the sponsor or the study site or members of their immediate family Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes. Any condition which, in the opinion of the investigator, causes xerostomia Dental prophylaxis within 4 weeks of screening Tongue or lip piercing or presence of dental implants Professional desensitising treatment within 12 weeks of screening Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of screening, scaling or root planning within 3 months of screening. Teeth bleaching within 12 weeks of screening Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of screening Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine Sensitive tooth not expected to respond to treatment with an over-the counter dentifrice in the opinion of the investigator. Use of a desensitising dentifrice within six weeks of screening (participant will be required to bring their current dentifrice to the site in order to verify the lack of known anti-sensitivity ingredients) Daily doses of a medication which, in the opinion of the investigator, could interfere with the perception of pain Currently taking antibiotics or have taken antibiotics within 2 weeks of baseline. Daily doses of a medication which, in the opinion of the investigator, causes xerostomia Individuals who require antibiotic prophylaxis for dental procedures Any participant who, in the judgment of the investigator, should not participate in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Cork
Country
Ireland

12. IPD Sharing Statement

Citations:
PubMed Identifier
27093773
Citation
Parkinson CR, Hughes N, Hall C, Whelton H, Gallob J, Mason S. Three randomized clinical trials to assess the short-term efficacy of anhydrous 0.454% w/w stannous fluoride dentifrices for the relief of dentin hypersensitivity. Am J Dent. 2016 Feb;29(1):25-32.
Results Reference
derived

Learn more about this trial

The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity

We'll reach out to this number within 24 hrs